PTK2 and cancer: While our data do support that YAP inhibitors may also exert synergistic effects to KRAS G12C inhibition, a capacity for small‐molecule‐mediated direct targeting of YAP remains elusive.[27] Thus, FAK inhibition can substitute for direct YAP inhibition to maximize the long‐term anti‐cancer outcomes from use of KRAS G12C inhibitors.